Poor outcome hebephrenic schizophrenia patients are clinically challenging. In this report, we demonstrate the usefulness of pimozide add-on thereapy to ongoing clozapine regime in a case who poorly reponded to clozapine, ECT and adequate trials with at least two conventional antipsychotics.
INTRODUCTION
Antipsychotics in high doses arc not necessarily successful in therapy resistance schizophrenia (Mardcr, 2000) whereas switching to another antipsychotic of a different class could be a better alternative.
In patients who arc refractory even to clozapine, coadministration of another antipsychotic, i.c, risperidone, loxapinc, sulpiride, olanzapine or pimozide may produce favourable results (Stubb et al., 2000) .
In this report, we highlight the successful use of pimozide to augment ongoing clozapine treatment.
CASE
Mrs. K, a 28-year lady, presented with a history of abnormal behaviour, which started insidiously and remained progressive for 14 years. She was found to have inappropriate laughter, muttering, odd gestures, social withdrawal and wandering tendency. In addition, she had disruptive behaviour and occasional urinary incontinence. She spoke irrelevantly and had poor personal care and social interest. On occasions, she would express paranoid ideas and hallucinatory behaviour.
On first contact, her mental status examination revealed poor grooming, inadequate eye contact, frequent grimacing, loosening of association and inappropriate affect. At this point, she was diagnosed as hebephrenic schizophrenia.
In the past, Mrs. K was treated with haloperidol 25 mg/day and chlorpromazine upto 700 mg/day without any response. About 7 years back, she was treated with a course of ECTs, which produced a minimal response, whereupon she was married. However, her clinical condition deteriorated withon 2 months. She was treated with olanzapine 40 mg/ day, 8 months back, for 12 weeks, but there was no response. 1-ater, she was given another course of 12 ECTs with a marginal, ill-sustained response.
After the diagnosis and baseline investigations, the patient was switched over to clozapine monotherapy. The dose was gradually increased to 450 mg/day, with weekly monitoring of blood counts. Even at this dose, she did not show any change in her behavior. However the dose could not be further increased because of excessive sedation. Pimozide was then added and gradually increased to 8 mg/day, along with trihexyphenidyl 4 mg/day. ECG was done at regular, frequent intervals. After addtion of pimozide, Mrs. K showed marked improvement in her behavior, particularly in affect, personal care, irrevalent talk, and grimacing. However, she continued to exhibit withdrawn behavior and had to be prompted to carry out her activities. This case was followed up for 6 months without any relapse of psychotic symptoms.
The term augmentation in this case refers to the use of two agents to achieve an enhanced antipsychotic response. Recent review on augmentation of clozapine (Stubb et al, 2000) did not mention about treatment with ECT, duration of illness, type of schizophrenia, type of antipsychotic drug that the patient was receiving, and presence of comorbidity. Friedman et al (1997) 
